Celgene (NASDAQ:CELG)

Stanford’s New Cancer Immunotherapy Starting Clinical Trials Could Spur a Big Pharma Bid

The concept behind cancer immunotherapy vaccines has been around since, believe it or not, 1891. This is when one Dr. William Coley began directly injecting tumors with bacteria, with 10% ...
Read Full Story »

13 Fresh Dividend Hikes and Stock Buybacks Too Big to Ignore

It is no secret that investors love when companies pay solid dividends and when they announce strong stock buyback plans. What they love even more is when companies increase their ...
Read Full Story »

Top Analyst Has 3 Large Cap Biotechs to Buy as Massive Selling Subsides

While the market has bounced back smartly over the past few sessions, one thing is for sure: the baby was tossed out with the proverbial bathwater in many sectors. Nowhere ...
Read Full Story »

Top Analyst Upgrades and Downgrades: ADT, CBOE, Celgene, JPMorgan, 3M, NetApp, Total, Tyson Foods, Weatherford and More

Monday's markets closed sharply higher after a recovery rally was seen on Friday, but Tuesday's opening bell was indicated to be weak for stocks. The bull market is just a ...
Read Full Story »

Major Biotechs See Rising Tide of Short Interest

The short interest data are out for the most recent settlement date, January 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Major Biopharma Catalysts on February’s FDA Calendar

Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials. The amount of risk involved ranges from fair to ...
Read Full Story »

Short Sellers Raise the Stakes in Major Biotechs

The short interest data are out for the most recent settlement date, January 12. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Why Celgene Is Betting Big on 2020 With Juno Acquisition

Juno Therapeutics Inc. (NASDAQ: JUNO) saw its shares take off early on Monday after it was announced that Celgene Corp. (NASDAQ: CELG) would be acquiring the cancer-focused firm. While this ...
Read Full Story »

Why Juno Therapeutics Is Soaring

Juno Therapeutics Inc. (NASDAQ: JUNO) saw its shares skyrocket early on Wednesday after The Wall Street Journal reported that Celgene Corp. (NASDAQ: CELG) was in talks to acquire the company. ...
Read Full Story »

Short Sellers Grow More Selective on Major Biotechs

The short interest data are out for the most recent settlement date, December 29. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Meet Merrill Lynch’s Top Biotech Picks for 2018

While 2017 was a strong year for the markets — especially technology stocks — biotech and health care stocks in general were only able to keep pace. The iShares Nasdaq ...
Read Full Story »

30 Big Biotech Events Coming in 2018

Over the past year, biotech companies have more or less kept pace with the markets, but they have the potential to break out in 2018. While they have been the ...
Read Full Story »

Top 10 Biopharma Events Kicking Off 2018

Biotechnology and pharmaceutical companies generally face a fair-to-great amount of risk based on the lengthy vetting process for their drug candidates, should a study come back negative or should a ...
Read Full Story »

Major Biotechs See Surge in Short Interest

The short interest data are out for the most recent settlement date, December 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Why Celgene Shares Took a Step Back

Celgene Corp. (NASDAQ: CELG) saw its shares take a step back early Friday after the firm announced in conjunction with the Lymphoma Study Association (LYSA) the results from a late-stage ...
Read Full Story »